Atrial Fibrillation : new anticoagulants more effective, and sometimes more economic
Published the 05.12.2017 at 07: 15
People suffering from atrial fibrillation, or atrial fibrillation should take blood thinners to thin the blood and prevent the formation of blood clots.
The most widely prescribed are anti-vitamin K (AVK), administered by the oral route. But a new generation of oral anticoagulants, the so-called “anticoagulants” direct action ” or ADO, dethrones the AVK. It is, in any event, the conclusion of an analysis published in the British Medical Journal.
Decrease in the risk of death
The researchers analyzed 23 trials, involving, in all, 94 656 patients. The aim : to compare the risk of cardiovascular accidents between treatments that include ADO, and those that include the AVK reference, warfarin.
According to the results, supporting this new generation of anticoagulants would reduce the risk of STROKE or embolism. The risk of death was also lower with the ADO with an AVK type warfarin.
A more economical choice
The side effects, the risks of gastrointestinal bleeding are higher with anticoagulants of direct action with the AVK, by contrast, cerebral hemorrhage, more serious, are also greatly reduced.
The researchers are also interested in the cost of these two types of treatment. After a new comparative study, comparing the costs of drugs, but also the costs of accidents and lives saved, it appears that the anticoagulants of direct action would be more economical, and, in particular, the apixaban.
In atrial fibrillation, and compared to anticoagulants traditional, the new anticoagulants of direct action to reduce the complications of this rhythm disturbance, as well as the cost of the treatment.